Development Of A Glucose-6-phosphate Dehydrogenase/ Haemoglobin Point-of-care Test For Malaria Elimination
Funder
National Health and Medical Research Council
Funding Amount
$560,608.00
Summary
Malaria elimination requires the use of specific anti-malarial drugs that treat the dormant malaria parasites in the liver. The use of these drugs in people with a deficiency of the glucose-6-phosphate dehydrogenase (G6PD) enzyme can lead to the catastrophic destruction of red blood cells and severe anaemia. There is a need for new G6PD diagnostic tests that can be delivered in remote, resource poor settings. This project will develop a G6PD point-of-care test to fast-track malaria elimination.
Development Of Antimalarial Histone Deacetylase Inhibitors
Funder
National Health and Medical Research Council
Funding Amount
$573,676.00
Summary
Human histone deacetylases (HDACs) are enzymes clinically validated as targets for cancer chemotherapy. Different HDAC enzymes are important for survival of infectious organisms, such as protozoan Plasmodium parasites that cause malaria. This project will develop promising drug leads that kill the parasites without damaging human cells through preclinical studies in mice towards a future clinical trial for the treatment of malaria in humans.